Wilson Martin sold $12K of RCKT
Wilson Martin (General Counsel) sold 3,493 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.38 on 2026-08-13.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the specific insider sale size, price, and post-transaction holdings; it does not include any company performance or forward-looking statements.
Market read
Traders may briefly monitor for insider selling trends, but this filing alone is unlikely to change valuation expectations.
What to watch
Insider sales can be tax- or diversification-driven; without follow-on purchases, option exercises, or a broader pattern, the signal is weak.
Background
The article is a SEC Form 4 insider transaction disclosure for Rocket Pharmaceuticals, Inc.
Ticker impact
Rocket Pharmaceuticals disclosed an insider open-market sale by General Counsel Wilson Martin of 3,493 shares at $3.3810 on 2026-08-13.
Likely limited near-term impact; traders may view it as mild negative sentiment but not a fundamental catalyst.
The filing is primary-source and time-stamped, but the transaction is small relative to the company’s scale and lacks accompanying company-specific news (no earnings, guidance, deal, or regulatory action).
Market effects
No clear sector read-through; insider sales are common and typically not informative without additional context.
None indicated.
None indicated.
Counterpoint
Absence of a stated 10b5-1 plan does not necessarily imply negative information; it may reflect personal liquidity needs or pre-existing arrangements not captured here.
Key entities
- issuerRocket Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderWilson Martin
General Counsel who sold 3,493 shares in an open-market sale.
